Herbas VPB

Print
EN | LT
LT - COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER
EN - COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER

Legal status

Patent not validated

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 31/4184 (2006.01)
A61K 31/506 (2006.01)
A61P 35/00 (2006.01)
A61K 31/5377 (2006.01)
European patent
(11) Number of the document 3125885
(13) Kind of document T
(96) European patent application number 15715805.6
Date of filing the European patent application 2015-04-02
(97) Date of publication of the European application 2017-02-08
(45) Date of publication and mention of the grant of the patent 2021-06-30
(46) Date of publication of the claims translation
PCT application
(86) Number PCT/GB2015/051042
Date 2015-04-02
PCT application publication
(87) Number WO 2015/150826
Date 2015-10-08
Priority applications
(30) Number Date Country code
201461975088 P 2014-04-04 US
201462013573 P 2014-06-18 US
Inventors
(72)
CROSS, Darren Anthony Edward , GB
EBERLEIN, Catherine Anne , GB
Grantee
(73) Astrazeneca AB , 151 85 Södertälje, SE
Title
(54) COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER
  COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER
Last update date 2021-09-30